



29th MAY 2020 | Number 5

XENOTHERA NEWS

Official news bulletin for XAV-19

EDITORIAL

by **Odile DUVAUX, President of XENOTHERA**

The journalist Olivier Magnan, who has been following the XENOTHERA adventure freely from the start, has highlighted two "rebels" in his magazine ÉcoRéseau ... I am intrigued by this rapprochement between two doctors who are not part of the Parisian in-crowd, which calls into question the notion of rebellion. A rebel is one who opposes, refuses or reacts. It is said that in France it is almost regarded as a quality, to be admired ... but it is also said to make life very difficult for our governments. Rebels are right to challenge fatalistic negativity, not people; are right to reject hasty conclusions, not authority; are right to react and launch debates, not just to make noise. As for XENOTHERA, I believe that our rebellion is strengthened by dreams (to heal), commitment (to act), and even a certain unconsciousness, allowing us to believe that it is possible to move mountains.



Click below to access the full ÉcoRéseau article:

**Deux médecins
« décalé/es » qui ne veulent
pas attendre le vaccin
contre le coronavirus**
Raoult-Duvaux : rebelles



MAIN FOCUS

Update on XAV-19 news

In this video, Odile Duvaux explains the therapeutic approach of XAV-19 to the Pays de la Loire Regional Council which has shown confidence in XENOTHERA and provided financial support:



TESTIMONY

Support of XENOTHERA

This week, we share the testimony of Sébastien Etienne who has been supporting XENOTHERA for 3 years, particularly during this period when the Nantes-based biotech has been working daily to make available its anti-Covid-19 treatment.

As President of the NSA Group, he speaks on behalf of a group of 70 leaders and entrepreneurs in the cleaning sector representing more than 50,000 employees:

Click on the image to go to his forum and / or listen to his podcast)





In the press...

Click on the logos to access articles.



Find our latest press releases:

- [XENOTHERA launches support campaign to finalise treatment for coronavirus infections, including Covid-19](#)
- [LFB signs agreement with biotech XENOTHERA](#)
- [The search for Covid-19 treatments: how can the antibodies developed by the French biotech XENOTHERA help? \(in french\)](#)

XENOTHERA :

XENOTHERA, created in 2014, is a Nantes-based biotech company which develops “humanized” polyclonal antibodies. Their technological platform is based on dual expertise in animal genetics and a mastery of immunology. The company has a complete portfolio of products, the first of which, LIS1, an immunosuppressant for transplants, has been in clinical trials since 2019. XENOTHERA is part of the Nantes scientific, medical and academic environment and is supported by the Pays de la Loire region’s Atlanpole competitiveness cluster. Since its creation, the company has raised 6 million euros in equity and has received support from the BPI.

For more information go to www.xenothera.com

Follow XENOTHERA on social media :



Contact :

XENOTHERA

1 rue Vauban - 44 000 Nantes
xenothera@izsogood.co